Page last updated: 2024-12-08

pld118

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-amino-4-methylenecyclopentane-1-carboxylic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID216240
CHEMBL ID343803
SCHEMBL ID117349
MeSH IDM0578134

Synonyms (33)

Synonym
bay-10-8888
cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1r,2s)-
(1r,2s)-2-amino-4-methylene-cyclopentanecarboxylic acid
icofungipen
pld-118
pld118
pld 118
CHEMBL343803
(-)-bay-10-8888
(1r,2s)-2-amino-4-methylidenecyclopentane-1-carboxylic acid
AKOS006340643
icofungipen [inn]
cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1r-cis)-
bay 10-8888
198022-65-0
i20202q8m8 ,
2-amino-4-methylenecyclopentane-1-carboxylic acid
(1r,2s)-2-amino-4-methylenecyclopentane-1-carboxylic acid
unii-i20202q8m8
156292-16-9
872691-28-6
RKOUGZGFAYMUIO-RITPCOANSA-N
SCHEMBL117349
DTXSID90173515
156292-48-7
cyclopentanecarboxylic acid, 2-amino-4-methylene-, cis- (9ci)
cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1s,2r)- (9ci)
2-amino-4-methylidenecyclopentane-1-carboxylic acid
bay 10-8888; pld 118
Q27280267
cyclopentanecarboxylic acid,2-amino-4-methylene-,cis-(9ci)
HY-106997
CS-0027085

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Icofungipen shows nearly complete oral bioavailability in a variety of species, and its in vivo efficacy indicates its potential for the oral treatment of yeast infections."( In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans.
Ergovic, G; Galic, T; Geschke, U; Hasenoehrl, A; Marsic, N; Mittendorf, J; Schmidt, A; Schoenfeld, W; Skerlev, M, 2006
)
0.33

Dosage Studied

ExcerptRelevanceReference
" PLD-118 demonstrated nonlinear plasma pharmacokinetics across the investigated dosage range, as was evident from a dose-dependent increase in plasma clearance and a dose-dependent decrease in the area under the plasma concentration-time curve."( Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans.
Bacher, J; Groll, AH; Kelaher, AM; Mickiene, D; Petraitiene, R; Petraitis, V; Sarafandi, AA; Sein, T; Walsh, TJ, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1380106Inhibition of Saccharomyces cerevisiae IleRS2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Emerging New Targets for the Treatment of Resistant Fungal Infections.
AID47250In vitro inhibitory activity against Candida albicans2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Novel antifungal beta-amino acids: synthesis and activity against Candida albicans.
AID1380099Half life in human2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Emerging New Targets for the Treatment of Resistant Fungal Infections.
AID1380102Oral bioavailability in rabbit2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Emerging New Targets for the Treatment of Resistant Fungal Infections.
AID1380101Oral bioavailability in dog2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Emerging New Targets for the Treatment of Resistant Fungal Infections.
AID1380100Oral bioavailability in rat2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Emerging New Targets for the Treatment of Resistant Fungal Infections.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (16.67)18.2507
2000's8 (66.67)29.6817
2010's2 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 14.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index14.74 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (14.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (15.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (84.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]